Bottom line
BHCFX vs PRHSX: the short answer
BHCFX (Baron Health Care Fund) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both mutual funds.
But PRHSX is far broader, holding 279 positions to 43 for BHCFX, so beyond the top names it adds exposure BHCFX doesn't have.
PRHSX is cheaper at 0.83% vs 1.1% — a difference of $27 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +2.5% for BHCFX.
Updated Nov 19, 2026
BHCFX vs PRHSX side by side
| BHCFX | PRHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Baron Select | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.1% | 0.83% |
| Annual cost per $10k | $110 | $83 |
| 10-yr cost on $10k (prospectus) | $1,340 | $1,025 |
| Max front load | — | — |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +10.0% | +17.7% |
| 5-yr return (annualized) | +2.5% | +4.2% |
| 10-yr return (annualized) | — | +9.1% |
| Best quarter | +24.6% | +23.5% |
| Worst quarter | −10.0% | −15.8% |
| Net assets (fund) | $114.1M | $11.9B |
| Number of holdings | 43 | 279 |
| Portfolio turnover | 74% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BHCFX | PRHSX | Difference |
|---|---|---|---|
| 2025 | +10.0% | +17.7% | −7.7% |
| 2024 | +1.3% | +1.8% | −0.6% |
| 2023 | +6.2% | +3.1% | +3.1% |
| 2022 | −17.1% | −12.2% | −4.9% |
| 2021 | +15.5% | +13.3% | +2.2% |
| 2020 | +47.4% | +30.1% | +17.3% |
| 2019 | +35.2% | +29.1% | +6.1% |
Source: Fund prospectus bar charts
Holdings overlap
13 of BHCFX's top 25 holdings also appear in PRHSX's top 25.
| Holding | BHCFX | PRHSX |
|---|---|---|
| Eli Lilly & Co | 13.66% | 14.28% |
| Johnson & Johnson | 5.56% | 6.63% |
| Thermo Fisher Scientific Inc | 3.91% | 2.52% |
| UnitedHealth Group Inc | 3.28% | 5.99% |
| Vertex Pharmaceuticals Inc | 2.61% | 2.28% |
| Merck & Co Inc | 2.48% | 4.01% |
| Guardant Health Inc | 2.17% | 1.23% |
| Kymera Therapeutics Inc | 2.01% | 0.89% |
| Gilead Sciences Inc | 1.99% | 2.82% |
| Natera Inc | 1.93% | 1.44% |
| Intuitive Surgical Inc | 1.74% | 1.87% |
| Protagonist Therapeutics Inc | 1.72% | 0.85% |
| Elevance Health Inc | 1.69% | 1.53% |
Source: SEC Form N-PORT
BHCFX top 10
- Eli Lilly & Co — 13.66%
- Mettler-Toledo International Inc — 5.60%
- Johnson & Johnson — 5.56%
- Argenx SE — 4.23%
- Thermo Fisher Scientific Inc — 3.91%
- Roivant Sciences Ltd — 3.88%
- Teva Pharmaceutical Industries Ltd — 3.86%
- Welltower Inc — 3.38%
- UnitedHealth Group Inc — 3.28%
- RadNet Inc — 3.24%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between BHCFX and PRHSX?
Which is cheaper, BHCFX or PRHSX?
Should I own both BHCFX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.